DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji-Won | ko |
dc.contributor.author | Chung, Sang Wan | ko |
dc.contributor.author | Pyo, Jung Yoon | ko |
dc.contributor.author | Chang, Sung Hae | ko |
dc.contributor.author | Kim, Min Uk | ko |
dc.contributor.author | Park, Chan Ho | ko |
dc.contributor.author | Lee, Ji Sung | ko |
dc.contributor.author | Lee, Jeong Seok | ko |
dc.contributor.author | Ha, You-Jung | ko |
dc.contributor.author | Kang, Eun Ha | ko |
dc.contributor.author | Lee, Yeon-Ah | ko |
dc.contributor.author | Park, Yong-Beom | ko |
dc.contributor.author | Lee, Eun Young | ko |
dc.contributor.author | Choe, Jung-Yoon | ko |
dc.date.accessioned | 2023-07-21T01:00:42Z | - |
dc.date.available | 2023-07-21T01:00:42Z | - |
dc.date.created | 2023-01-09 | - |
dc.date.issued | 2023-07 | - |
dc.identifier.citation | RHEUMATOLOGY, v.62, no.7, pp.2377 - 2385 | - |
dc.identifier.issn | 1462-0324 | - |
dc.identifier.uri | http://hdl.handle.net/10203/310740 | - |
dc.description.abstract | Objective To examine the association between MTX, LEF and tacrolimus use and the progression of RA-associated interstitial lung disease (ILD). Methods The Korean RA-ILD cohort prospectively enrolled patients with RA-associated ILD at multiple centres from 2015 to 2018 and followed up with them for 3 years. ILD progression was defined by any of the followings: a decrease of >= 10% in forced vital capacity, a decrease of >= 15% in the diffusing capacity of the lung for carbon monoxide, or death from respiratory failure. Results Of 143 patients, 64 patients experienced ILD progression during a median follow-up period of 33 months. The use of MTX [adjusted hazard ratio (aHR), 1.06; 95% CI, 0.59, 1.89], LEF (aHR, 1.75; 95% CI, 0.88, 3.46) and tacrolimus (aHR, 0.94; 95% CI, 0.52, 1.72) did not increase the risk of ILD progression. However, the association between LEF use and the risk of ILD progression was significant in subgroups with poor lung function (aHR, 8.42; 95% CI, 2.61, 27.15). Older age, male sex, a shorter RA duration, higher RA disease activity and extensive disease at baseline were independently associated with ILD progression. Conclusion None of the three treatments increased the risk of RA-associated ILD progression, except for LEF, which increased the risk of ILD progression in patients with severe ILD. The appropriate use of conventional synthetic disease-modifying antirheumatic drugs considering RA disease activity and ILD severity would be important for the management of RA-associated ILD. | - |
dc.language | English | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.title | Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease | - |
dc.type | Article | - |
dc.identifier.wosid | 000897732800001 | - |
dc.identifier.scopusid | 2-s2.0-85164240714 | - |
dc.type.rims | ART | - |
dc.citation.volume | 62 | - |
dc.citation.issue | 7 | - |
dc.citation.beginningpage | 2377 | - |
dc.citation.endingpage | 2385 | - |
dc.citation.publicationname | RHEUMATOLOGY | - |
dc.identifier.doi | 10.1093/rheumatology/keac651 | - |
dc.contributor.localauthor | Lee, Jeong Seok | - |
dc.contributor.nonIdAuthor | Kim, Ji-Won | - |
dc.contributor.nonIdAuthor | Chung, Sang Wan | - |
dc.contributor.nonIdAuthor | Pyo, Jung Yoon | - |
dc.contributor.nonIdAuthor | Chang, Sung Hae | - |
dc.contributor.nonIdAuthor | Kim, Min Uk | - |
dc.contributor.nonIdAuthor | Park, Chan Ho | - |
dc.contributor.nonIdAuthor | Lee, Ji Sung | - |
dc.contributor.nonIdAuthor | Ha, You-Jung | - |
dc.contributor.nonIdAuthor | Kang, Eun Ha | - |
dc.contributor.nonIdAuthor | Lee, Yeon-Ah | - |
dc.contributor.nonIdAuthor | Park, Yong-Beom | - |
dc.contributor.nonIdAuthor | Lee, Eun Young | - |
dc.contributor.nonIdAuthor | Choe, Jung-Yoon | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | RA | - |
dc.subject.keywordAuthor | interstitial lung disease | - |
dc.subject.keywordAuthor | MTX | - |
dc.subject.keywordAuthor | LEF | - |
dc.subject.keywordAuthor | tacrolimus | - |
dc.subject.keywordAuthor | progression-free survival | - |
dc.subject.keywordPlus | IDIOPATHIC PULMONARY-FIBROSIS | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | ACUTE EXACERBATION | - |
dc.subject.keywordPlus | AMERICAN-COLLEGE | - |
dc.subject.keywordPlus | INJURY | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | PNEUMONITIS | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.